Liepina Lelde, Kalnina Marija Luize, Micule Ieva, Gailite Linda, Rots Dmitrijs, Kalnina Julija, Strautmanis Jurgis, Celmina Marta
Department of Neurology and Neurosurgery, Children's Clinical University Hospital, Riga, Latvia.
Faculty of Residency, Riga Stradins University, Riga, Latvia.
Am J Med Genet A. 2022 Apr;188(4):1263-1279. doi: 10.1002/ajmg.a.62613. Epub 2021 Dec 23.
Kohlschütter-Tönz syndrome (KTS) is a rare, autosomal recessive syndrome characterized by a triad of epilepsy, amelogenesis imperfecta and severe global developmental delay. It was first described in a Swiss family in 1974 by Alfried Kohlschütter and Otmar Tönz. It is caused by pathogenic variants in the ROGDI gene. To the best of our knowledge, there are currently 43 patients with a confirmed ROGDI gene pathogenic variant reported. Here, we review in detail the clinical manifestations of KTS, provide an overview of all reported genetically confirmed patients, and document an additional case of KTS-a 6-year-old Latvian girl-with a confirmed ROGDI gene pathogenic variant. In contrast to previous reports, we detected idiopathic bilateral nephrocalcinosis in this newly identified KTS patient. Perampanel proved an effective treatment for our patient with prolonged super-refractory status epilepticus. In order to better characterize this rare syndrome and its clinical course, it is important to report any additional symptoms and also the effectiveness of used therapies. Future research should focus on elucidating the mechanisms by which the absence/insufficiency of ROGDI-encoded protein causes the clinical manifestations of KTS. This knowledge could shape possible ways of influencing the disease's natural history with more effective therapies.
科尔施许特-滕茨综合征(KTS)是一种罕见的常染色体隐性综合征,其特征为癫痫、牙釉质发育不全和严重的全面发育迟缓三联征。1974年,阿尔弗里德·科尔施许特和奥马尔·滕茨在一个瑞士家庭中首次描述了该综合征。它由ROGDI基因的致病变异引起。据我们所知,目前已报道43例确诊为ROGDI基因致病变异的患者。在此,我们详细回顾了KTS的临床表现,概述了所有已报道的基因确诊患者,并记录了另外一例KTS病例——一名6岁的拉脱维亚女孩,其ROGDI基因致病变异得到确诊。与先前的报道不同,我们在这名新确诊的KTS患者中检测到特发性双侧肾钙质沉着症。吡仑帕奈被证明对我们这位患有长时间超难治性癫痫持续状态的患者是一种有效的治疗方法。为了更好地描述这种罕见综合征及其临床病程,报告任何额外症状以及所用治疗方法的有效性都很重要。未来的研究应侧重于阐明ROGDI编码蛋白的缺失/不足导致KTS临床表现的机制。这些知识可能会形成通过更有效的治疗方法影响该疾病自然病程的可能途径。